Similar immunomodulatory roles of DLX2 have been reported in lung squamous cell carcinoma, and DLX2 was found to be associated with the IPS of PD-1/PD-L1 blockade as well as CTLA-4 combined with PD-1/PD-L1 blockade (27). Here, PDCD1 is linked to squamous cell lung carcinoma.